| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 29,200 | 29,400 | 19:53 | |
| 29,300 | 29,450 | 19:47 |
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 13:06 | Newron Pharmaceuticals S.p.A.: EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan | Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral... ► Artikel lesen | |
| 07:47 | Newron-Partner EA Pharma startet zulassungsrelevante Studie mit Evenamide | ||
| 07:03 | EQS-News: Newron Pharmaceuticals S.p.A.: EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan | EQS-News: Newron Pharmaceuticals S.p.A.
/ Key word(s): Study
Newron Pharmaceuticals S.p.A.: EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical... ► Artikel lesen | |
| Di | NEWRON PHARMACEUTICALS SPA: Struktur in der Ruhe | ||
| Di | Newron Pharmaceuticals S.p.A.: Newron Further Expands Intellectual Property Portfolio for Evenamide with New EU Composition of Matter Patent | Ad hoc announcement pursuant to Art. 53 LR EP4615820 "Crystalline Forms of Evenamide" is expected to extend asset exclusivity in EU into 2044 Evenamide is currently being investigated in... ► Artikel lesen |
